Do you re-load with monthly doses when switching a patient with DME from aflibercept to faricimab, or do you transition directly to a treat-and-extend schedule?

When I switch from one anti-VEGF agent to another, I start with the same treatment interval I was using with the previous agent, so I can assess the comparative efficacy of the two agents. Once I have determined the new agent is more effective, I proceed immediately to a treat-and-extend dosing regi...